Michael Anstey

Mike graduated with a 1st Class Honors degree in Biology from Queen's University, Canada, and earned his DPhil in Zoology from Oxford University, where he was the Hope Scholar.

Michael is a Partner specialising in life sciences and health care investments.

Before joining CIC he was a Principal in the Health Care Practice Area at The Boston Consulting Group. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan. Prior to BCG, Michael was an Investment Analyst at Oxford Capital Partners.

​

Michael was also co-founder of an early-stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease.

​

Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford.

​

Michael manages CIC's investments in Nuclera, Bicycle Therapeutics (NASDAQ: BCYC), Epitopea, TRIMTech Therapeutics, Immutrin, Congenica, and Start Codon.

Michael served his fellowship at Cambridge Innovation Capital under the mentorship of Victor Christou. He is a member of Class 22.